Clinical radiobiology of glioblastoma multiforme: estimation of tumor control probability from various radiotherapy fractionation schemes (387 views)
Strahlenther Onkol (ISSN: 0179-7158, 0179-7158linking), 2014 Oct; 190(10): 925-932.
Export to BibTeX Export to EndNote
Paper type: Journal Article, Evaluation Studies, Validation Studies,
Impact factor: 2.914, 5-year impact factor: 2.402
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84919873901&partnerID=40&md5=8a68c7c1f7d3f80637d3bcd33c9d7fe9
Keywords: Accelerated Proliferation, Glioblastoma Multiforme, Hypofractionation, Intrinsic Radiosensitivity, Repopulation Kinetics, Carmustine, Temozolomide, Article, Cancer Adjuvant Therapy, Cancer Control, Cancer Radiotherapy, Cancer Surgery, Clinical Study, Controlled Study, Human, Hypothesis, Major Clinical Study, Outcome Assessment, Radiation Dose, Radiobiology, Biological Model, Brain Neoplasms, Computer Assisted Radiotherapy, Computer Simulation, Evaluation Study, Pathophysiology, Procedures, Prognosis, Radiation Dose Fractionation, Reproducibility, Risk Assessment, Sensitivity And Specificity, Statistical Analysis, Statistical Model, Statistics And Numerical Data, Treatment Outcome, Validation Study, Data Interpretation, Outcome Assessment (health Care), Radiation Tolerance, Conformal, Reproducibility Of Results, Brain Neoplasms Physiopathology Radiotherapy, Glioblastoma Physiopathology Radiotherapy, Outcome Assessment (health Care) Methods, Conformal Statistics, Risk Assessment Methods,
Affiliations:
*** IBB - CNR ***
Unit of Nuclear Medicine, Department of Radiation and Metabolic Therapies, I.R.C.C.S.-Regional-Cancer-Hospital-C.R.O.B, 1-Padre-Pio-Street, Rionero-in-Vulture, Italy, ppiern@libero.it.
Radiation Oncology Department, Sacro Cuore – Don Calabria HospitalNegrar, Verona, Italy
Laboratory of Preclinical and Translational Research, I.R.C.C.S.-Regional-Cancer-Hospital-C.R.O.BRionero-in-Vulture, Italy
Unit of Radiation Oncology, Department of Medicine Surgery and Neurological Sciences, University of Siena and Tuscany Tumor InstituteSiena, Italy
Unit of Radiotherapy, Department of Radiation and Metabolic Therapies, I.R.C.C.S.-Regional-Cancer-Hospital-C.R.O.BRionero-in-Vulture, Italy
References:
Balducci, M., Apicella, G., Manfrida, S., Mangiola, A., Fiorentino, A., Azario, L., D’Agostino, G.R., Cellini, N., Single-Arm Phase II Study of Conformal Radiation Therapy and Temozolomide plus fractionated Stereotactic Conformal Boost in High grade Gliomas (2010) Strahlen Onkol, 186 (10), pp. 558-56
Balducci, M., Chiesa, S., Diletto, B., D’Agostino, G.R., Mangiola, A., Manfrida, S., Mantini, G., Valentini, V., Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study (2012) Neuro Oncol, 14 (1), pp. 79-86. , PID: 21993440, COI: 1:CAS:528:DC%2BC38XjsVCntrg%3D
Balducci, M., Fiorentino, A., De Bonis, P., Chiesa, S., Mangiola, A., Mattiucci, G.C., D’Agostino, G.R., Valentini, V., Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials (2013) Strahlen Onkol, 189 (11), pp. 926-931. , COI: 1:STN:280:DC%2BC3sbjvFOrsw%3D%3D
Bao, S., Wu, Q., Mc Lendon, R.E., Hao, Y., Shi, Q., Hjelmeland, A.B., Dewhirst, M.W., Rich, J.N., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response (2006) Nature, 444 (7120), pp. 756-760. , PID: 17051156, COI: 1:CAS:528:DC%2BD28Xht1OntbzP
Phase III Trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93–72-52 and Southwest Oncology Group 9503 Trials (2006) J Clin Oncol, 24 (24), pp. 3871-3879
Ciammella, P., Galeandro, M., D’Abbiero, N., Podgornii, A., Pisanello, A., Botti, A., Cagni, E., Iotti, C., Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience (2013) Clin Neurol Neurosurg, 115 (9), pp. 1609-1614. , PID: 23453151
Collett, D., (1994) Modelling survival data-in medical research, pp. 22-26. , Chapman and Hall, London:
Daşu, A., Toma-Daşu, I., Fowler, J.F., Should single distributed parameters be used to explain the steepness of tumour control probability curves? (2003) Phys Med Biol, 48, pp. 387-397. , PID: 12608614
Efron, B., Censored data and the bootstrap (1981) J Am Stat Ass, 76, pp. 312-319
Fietkau, R., Putz, F., Lahmer, G., Semrau, S., Buslei, R., Can MGMT promoter methylation status be used as a prognostic and predictive marker for glioblastomamultiforme at the present time?: a word of caution (2013) Strahlenther Onkol, 189 (12), pp. 993-995. , PID: 24177536, COI: 1:STN:280:DC%2BC2c7hsFehsQ%3D%3D
Guckenberger, M., Mayer, M., Buttmann, M., Vince, G.H., Sweeney, R.A., Flentje, M., Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme (2011) Strahlen Onkol, 187 (9), pp. 548-554
Hegi, M.E., Diserens, A.C., Gorlia, T., Hamou, M.F., de Tribolet, N., Weller, M., Kros, J.M., Stupp, R., MGMT gene silencing and benefit from temozolomide in glioblastoma (2005) N Engl J Med, 352 (10), pp. 997-1003. , PID: 15758010, COI: 1:CAS:528:DC%2BD2MXit1Wktro%3D
Jones, T.S., Holland, E.C., Standard of care therapy for malignant glioma and its effect on tumor and stromal cells (2012) Oncogene, 31, pp. 1995-2006. , PID: 21909136, COI: 1:CAS:528:DC%2BC3MXhtFGntbnE
Lee, S.W., Fraass, B.A., Marsh, L.H., Herbort, K., Gebarski, S.S., Martel, M.K., Radany, E.H., Sandler, H.M., Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study (1999) Int J Radiat Oncol Biol Phys, 43, pp. 79-88. , PID: 9989517, COI: 1:STN:280:DyaK1M7kt1KhsQ%3D%3D
Massaccesi, M., Ferro, M., Cilla, S., Balducci, M., Deodato, F., Macchia, G., Valentini, V., Morganti, A.G., Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1) (2013) Int J Clin Oncol, 18 (5), pp. 784-791. , PID: 22892797, COI: 1:CAS:528:DC%2BC3sXhs1GktbrM
Mizumoto, M., Okumura, T., Ishikawa, E., Yamamoto, T., Takano, S., Matsumura, A., Oshiro, Y., Tsuboi, K., Reirradiation for recurrent malignant brain tumor with radiotherapy or proton beam therapy. Technical considerations based on experience at a single institution (2013) Strahlenther Onkol, 189 (8), pp. 656-663. , PID: 23824106, COI: 1:STN:280:DC%2BC3sjnvVajtQ%3D%3D
Morganti, A.G., Balducci, M., Salvati, M., Esposito, V., Romanelli, P., Ferro, M., Calista, F., Cantore, G.P., A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma (2010) Int J Radiat Oncol Biol Phys, 77, pp. 92-97. , PID: 19683876, COI: 1:CAS:528:DC%2BC3cXkvFKkur4%3D
Nakagawa, K., Aoki, Y., Fujimaki, T., Tago, M., Terahara, A., Karasawa, K., Sakata, K., Akanuma, A., High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme (1998) Int J Radiat Oncol Biol Phys, 40 (5), pp. 1141-1149. , PID: 9539570, COI: 1:STN:280:DyaK1c7pvV2kug%3D%3D
Okunieff, P., Morgan, D., Niemierko, A., Radiation dose-response of human tumor (1995) Int J Radiat Oncol Biol Phys, 32, pp. 1227-1237. , PID: 7607946, COI: 1:STN:280:DyaK2Mzjt1SktA%3D%3D
Panet-Raymond, V., Souhami, L., Roberge, D., Kavan, P., Shakibnia, L., Muanza, T., Lambert, C., Shenouda, G., Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy (2009) Int J Radiat Oncol Biol Phys, 73 (2), pp. 473-478. , PID: 18554821, COI: 1:CAS:528:DC%2BD1MXntVCgsQ%3D%3D
Pedicini, P., In regard to Pedicini et al (2013) Int J Radiat Oncol Biol, 87 (5), p. 858
Pedicini, P., Nappi, A., Strigari, L., Jereczek-Fossa, B.A., Alterio, D., Cremonesi, M., Botta, F., Salvatore, M., Correlation between EGFR expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma (2012) Radiat Oncol, 7, p. 143. , PID: 22920680
Pedicini, P., Caivano, R., Strigari, L., Benassi, M., Fiorentino, A., Fusco, V., In regard to Miralbell et al. Re: Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy (2013) Int J Radiat Oncol Biol Phys, 85 (1), pp. 10-11. , PID: 23237001
Pedicini, P., Fiorentino, A., Improta, G., Nappi, A., Salvatore, M., Storto, G., Estimate of the accelerated proliferation by protein tyrosine phosphatase (PTEN) over expression in postoperative radiotherapy of head and neck squamous cell carcinoma (2013) Clin Transl Oncol, 15 (11), pp. 919-924. , PID: 23460560, COI: 1:CAS:528:DC%2BC3sXhs1Wjur3F
Pedicini, P., Strigari, L., Benassi, M., Estimation of a self-consistent set of radiobiological parameters from hypofractionated versus standard radiation therapy of prostate cancer (2013) Int J Radiat Oncol Biol Phys, 85 (5), pp. e231-e237
Roberts, S.A., Hendry, J.H., A realistic closed-form radiobiological model of clinical tumor-control data incorporating intertumor heterogeneity (1998) Int J Radiat Oncol Biol Phys, 41 (3), pp. 689-699. , PID: 9635721, COI: 1:STN:280:DyaK1c3pslKntg%3D%3D
Souhami, L., Seiferheld, W., Brachman, D., Podgorsak, E.B., Werner-Wasik, M., Lustig, R., Schultz, C.J., Curran, W.J., Jr., Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol (2004) Int J Radiat Oncol Biol Phys, 60 (3), pp. 853-860. , PID: 15465203
Stupp, R., Mason, W., Van der Bent, M., Weller, M., Fisher, B., Taphoorn, M.J., Belanger, K., National Cancer Institute of Canada Clinical Trials Group, Radiotherapy plus concomitant and adjuvant Temozolomide for glioblatoma (2005) N Engl J Med, 352 (10), pp. 987-996. , PID: 15758009, COI: 1:CAS:528:DC%2BD2MXit1Wksbk%3D
Terasaki, M., Eto, T., Nakashima, S., Okada, Y., Ogo, E., Sugita, Y., Tokutomi, T., Shigemori, M., A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme (2011) J Neurooncol, 102, pp. 247-253. , PID: 20640480, COI: 1:CAS:528:DC%2BC3MXivFyit7s%3D
Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03 (2009) Int J Radiat Oncol Biol Phys, 73 (3), pp. 699-708
Verhaak, R.G., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., Miller, C.R., Hayes, D.N., An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1 (2010) Cancer Cell, 17 (1), pp. 98-110. , PID: 20129251, COI: 1:CAS:528:DC%2BC3cXkvFKgsL4%3D
Walker, M.D., Strike, T.A., An evaluation of methyl-CCNU, BCNU and radiotherapy in the treatment of malignant glioma (1976) Proc Am Assoc Cancer Res, 17, p. 63. , COI: 1:CAS:528:DyaE28Xhtlejurk%3D
Dasu, A., Toma-Dasu, I., Fowler, J.F., Should single distributed parameters be used to explain the steepness of tumour control probability curves? (2003) Phys Med Biol, 48, pp. 387-397. , PID: 12608614
Strahlenther Onkol (ISSN: 0179-7158, 0179-7158linking), 2014 Oct; 190(10): 925-932.
Export to BibTeX Export to EndNote
Paper type: Journal Article, Evaluation Studies, Validation Studies,
Impact factor: 2.914, 5-year impact factor: 2.402
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84919873901&partnerID=40&md5=8a68c7c1f7d3f80637d3bcd33c9d7fe9
Keywords: Accelerated Proliferation, Glioblastoma Multiforme, Hypofractionation, Intrinsic Radiosensitivity, Repopulation Kinetics, Carmustine, Temozolomide, Article, Cancer Adjuvant Therapy, Cancer Control, Cancer Radiotherapy, Cancer Surgery, Clinical Study, Controlled Study, Human, Hypothesis, Major Clinical Study, Outcome Assessment, Radiation Dose, Radiobiology, Biological Model, Brain Neoplasms, Computer Assisted Radiotherapy, Computer Simulation, Evaluation Study, Pathophysiology, Procedures, Prognosis, Radiation Dose Fractionation, Reproducibility, Risk Assessment, Sensitivity And Specificity, Statistical Analysis, Statistical Model, Statistics And Numerical Data, Treatment Outcome, Validation Study, Data Interpretation, Outcome Assessment (health Care), Radiation Tolerance, Conformal, Reproducibility Of Results, Brain Neoplasms Physiopathology Radiotherapy, Glioblastoma Physiopathology Radiotherapy, Outcome Assessment (health Care) Methods, Conformal Statistics, Risk Assessment Methods,
Affiliations:
*** IBB - CNR ***
Unit of Nuclear Medicine, Department of Radiation and Metabolic Therapies, I.R.C.C.S.-Regional-Cancer-Hospital-C.R.O.B, 1-Padre-Pio-Street, Rionero-in-Vulture, Italy, ppiern@libero.it.
Radiation Oncology Department, Sacro Cuore – Don Calabria HospitalNegrar, Verona, Italy
Laboratory of Preclinical and Translational Research, I.R.C.C.S.-Regional-Cancer-Hospital-C.R.O.BRionero-in-Vulture, Italy
Unit of Radiation Oncology, Department of Medicine Surgery and Neurological Sciences, University of Siena and Tuscany Tumor InstituteSiena, Italy
Unit of Radiotherapy, Department of Radiation and Metabolic Therapies, I.R.C.C.S.-Regional-Cancer-Hospital-C.R.O.BRionero-in-Vulture, Italy
References:
Balducci, M., Apicella, G., Manfrida, S., Mangiola, A., Fiorentino, A., Azario, L., D’Agostino, G.R., Cellini, N., Single-Arm Phase II Study of Conformal Radiation Therapy and Temozolomide plus fractionated Stereotactic Conformal Boost in High grade Gliomas (2010) Strahlen Onkol, 186 (10), pp. 558-56
Balducci, M., Chiesa, S., Diletto, B., D’Agostino, G.R., Mangiola, A., Manfrida, S., Mantini, G., Valentini, V., Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study (2012) Neuro Oncol, 14 (1), pp. 79-86. , PID: 21993440, COI: 1:CAS:528:DC%2BC38XjsVCntrg%3D
Balducci, M., Fiorentino, A., De Bonis, P., Chiesa, S., Mangiola, A., Mattiucci, G.C., D’Agostino, G.R., Valentini, V., Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials (2013) Strahlen Onkol, 189 (11), pp. 926-931. , COI: 1:STN:280:DC%2BC3sbjvFOrsw%3D%3D
Bao, S., Wu, Q., Mc Lendon, R.E., Hao, Y., Shi, Q., Hjelmeland, A.B., Dewhirst, M.W., Rich, J.N., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response (2006) Nature, 444 (7120), pp. 756-760. , PID: 17051156, COI: 1:CAS:528:DC%2BD28Xht1OntbzP
Phase III Trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93–72-52 and Southwest Oncology Group 9503 Trials (2006) J Clin Oncol, 24 (24), pp. 3871-3879
Ciammella, P., Galeandro, M., D’Abbiero, N., Podgornii, A., Pisanello, A., Botti, A., Cagni, E., Iotti, C., Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience (2013) Clin Neurol Neurosurg, 115 (9), pp. 1609-1614. , PID: 23453151
Collett, D., (1994) Modelling survival data-in medical research, pp. 22-26. , Chapman and Hall, London:
Daşu, A., Toma-Daşu, I., Fowler, J.F., Should single distributed parameters be used to explain the steepness of tumour control probability curves? (2003) Phys Med Biol, 48, pp. 387-397. , PID: 12608614
Efron, B., Censored data and the bootstrap (1981) J Am Stat Ass, 76, pp. 312-319
Fietkau, R., Putz, F., Lahmer, G., Semrau, S., Buslei, R., Can MGMT promoter methylation status be used as a prognostic and predictive marker for glioblastomamultiforme at the present time?: a word of caution (2013) Strahlenther Onkol, 189 (12), pp. 993-995. , PID: 24177536, COI: 1:STN:280:DC%2BC2c7hsFehsQ%3D%3D
Guckenberger, M., Mayer, M., Buttmann, M., Vince, G.H., Sweeney, R.A., Flentje, M., Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme (2011) Strahlen Onkol, 187 (9), pp. 548-554
Hegi, M.E., Diserens, A.C., Gorlia, T., Hamou, M.F., de Tribolet, N., Weller, M., Kros, J.M., Stupp, R., MGMT gene silencing and benefit from temozolomide in glioblastoma (2005) N Engl J Med, 352 (10), pp. 997-1003. , PID: 15758010, COI: 1:CAS:528:DC%2BD2MXit1Wktro%3D
Jones, T.S., Holland, E.C., Standard of care therapy for malignant glioma and its effect on tumor and stromal cells (2012) Oncogene, 31, pp. 1995-2006. , PID: 21909136, COI: 1:CAS:528:DC%2BC3MXhtFGntbnE
Lee, S.W., Fraass, B.A., Marsh, L.H., Herbort, K., Gebarski, S.S., Martel, M.K., Radany, E.H., Sandler, H.M., Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study (1999) Int J Radiat Oncol Biol Phys, 43, pp. 79-88. , PID: 9989517, COI: 1:STN:280:DyaK1M7kt1KhsQ%3D%3D
Massaccesi, M., Ferro, M., Cilla, S., Balducci, M., Deodato, F., Macchia, G., Valentini, V., Morganti, A.G., Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1) (2013) Int J Clin Oncol, 18 (5), pp. 784-791. , PID: 22892797, COI: 1:CAS:528:DC%2BC3sXhs1GktbrM
Mizumoto, M., Okumura, T., Ishikawa, E., Yamamoto, T., Takano, S., Matsumura, A., Oshiro, Y., Tsuboi, K., Reirradiation for recurrent malignant brain tumor with radiotherapy or proton beam therapy. Technical considerations based on experience at a single institution (2013) Strahlenther Onkol, 189 (8), pp. 656-663. , PID: 23824106, COI: 1:STN:280:DC%2BC3sjnvVajtQ%3D%3D
Morganti, A.G., Balducci, M., Salvati, M., Esposito, V., Romanelli, P., Ferro, M., Calista, F., Cantore, G.P., A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma (2010) Int J Radiat Oncol Biol Phys, 77, pp. 92-97. , PID: 19683876, COI: 1:CAS:528:DC%2BC3cXkvFKkur4%3D
Nakagawa, K., Aoki, Y., Fujimaki, T., Tago, M., Terahara, A., Karasawa, K., Sakata, K., Akanuma, A., High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme (1998) Int J Radiat Oncol Biol Phys, 40 (5), pp. 1141-1149. , PID: 9539570, COI: 1:STN:280:DyaK1c7pvV2kug%3D%3D
Okunieff, P., Morgan, D., Niemierko, A., Radiation dose-response of human tumor (1995) Int J Radiat Oncol Biol Phys, 32, pp. 1227-1237. , PID: 7607946, COI: 1:STN:280:DyaK2Mzjt1SktA%3D%3D
Panet-Raymond, V., Souhami, L., Roberge, D., Kavan, P., Shakibnia, L., Muanza, T., Lambert, C., Shenouda, G., Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy (2009) Int J Radiat Oncol Biol Phys, 73 (2), pp. 473-478. , PID: 18554821, COI: 1:CAS:528:DC%2BD1MXntVCgsQ%3D%3D
Pedicini, P., In regard to Pedicini et al (2013) Int J Radiat Oncol Biol, 87 (5), p. 858
Pedicini, P., Nappi, A., Strigari, L., Jereczek-Fossa, B.A., Alterio, D., Cremonesi, M., Botta, F., Salvatore, M., Correlation between EGFR expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma (2012) Radiat Oncol, 7, p. 143. , PID: 22920680
Pedicini, P., Caivano, R., Strigari, L., Benassi, M., Fiorentino, A., Fusco, V., In regard to Miralbell et al. Re: Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy (2013) Int J Radiat Oncol Biol Phys, 85 (1), pp. 10-11. , PID: 23237001
Pedicini, P., Fiorentino, A., Improta, G., Nappi, A., Salvatore, M., Storto, G., Estimate of the accelerated proliferation by protein tyrosine phosphatase (PTEN) over expression in postoperative radiotherapy of head and neck squamous cell carcinoma (2013) Clin Transl Oncol, 15 (11), pp. 919-924. , PID: 23460560, COI: 1:CAS:528:DC%2BC3sXhs1Wjur3F
Pedicini, P., Strigari, L., Benassi, M., Estimation of a self-consistent set of radiobiological parameters from hypofractionated versus standard radiation therapy of prostate cancer (2013) Int J Radiat Oncol Biol Phys, 85 (5), pp. e231-e237
Roberts, S.A., Hendry, J.H., A realistic closed-form radiobiological model of clinical tumor-control data incorporating intertumor heterogeneity (1998) Int J Radiat Oncol Biol Phys, 41 (3), pp. 689-699. , PID: 9635721, COI: 1:STN:280:DyaK1c3pslKntg%3D%3D
Souhami, L., Seiferheld, W., Brachman, D., Podgorsak, E.B., Werner-Wasik, M., Lustig, R., Schultz, C.J., Curran, W.J., Jr., Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol (2004) Int J Radiat Oncol Biol Phys, 60 (3), pp. 853-860. , PID: 15465203
Stupp, R., Mason, W., Van der Bent, M., Weller, M., Fisher, B., Taphoorn, M.J., Belanger, K., National Cancer Institute of Canada Clinical Trials Group, Radiotherapy plus concomitant and adjuvant Temozolomide for glioblatoma (2005) N Engl J Med, 352 (10), pp. 987-996. , PID: 15758009, COI: 1:CAS:528:DC%2BD2MXit1Wksbk%3D
Terasaki, M., Eto, T., Nakashima, S., Okada, Y., Ogo, E., Sugita, Y., Tokutomi, T., Shigemori, M., A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme (2011) J Neurooncol, 102, pp. 247-253. , PID: 20640480, COI: 1:CAS:528:DC%2BC3MXivFyit7s%3D
Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03 (2009) Int J Radiat Oncol Biol Phys, 73 (3), pp. 699-708
Verhaak, R.G., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., Miller, C.R., Hayes, D.N., An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1 (2010) Cancer Cell, 17 (1), pp. 98-110. , PID: 20129251, COI: 1:CAS:528:DC%2BC3cXkvFKgsL4%3D
Walker, M.D., Strike, T.A., An evaluation of methyl-CCNU, BCNU and radiotherapy in the treatment of malignant glioma (1976) Proc Am Assoc Cancer Res, 17, p. 63. , COI: 1:CAS:528:DyaE28Xhtlejurk%3D
Dasu, A., Toma-Dasu, I., Fowler, J.F., Should single distributed parameters be used to explain the steepness of tumour control probability curves? (2003) Phys Med Biol, 48, pp. 387-397. , PID: 12608614
Clinical radiobiology of glioblastoma multiforme: estimation of tumor control probability from various radiotherapy fractionation schemes
BACKGROUND AND PURPOSE: The aim of this study was to estimate a radiobiological set of parameters from the available clinical data on glioblastoma (GB).; PATIENTS AND METHODS: A number of clinical trial outcomes from patients affected by GB and treated with surgery and adjuvant radiochemotherapy were analyzed to estimate a set of radiobiological parameters for a tumor control probability (TCP) model. The analytical/graphical method employed to fit the clinical data allowed us to estimate the intrinsic tumor radiosensitivity (alpha), repair capability (b), and repopulation doubling time (T d ) in a first phase, and subsequently the number of clonogens (N) and kick-off time for accelerated proliferation (T(k)). The results were used to formulate a hypothesis for a schedule expected to significantly improve local control. The 95 % confidence intervals (CI(95 %)) of all parameters are also discussed.; RESULTS: The pooled analysis employed to estimate the parameters summarizes the data of 559 patients, while the studies selected to verify the results summarize data of 104 patients. The best estimates and the CI(95 %) are alpha = 0.12 Gy⁻ (0.10-0.14), b = 0.015 Gy⁻ (0.013-0.020), alpha/b = 8 Gy (5.0-10.8), T(d) = 15.4 days (13.2-19.5), N = 1.10⁴(1.2.10 - 1.10⁵), and T(k) = 37 days (29-46). The dose required to offset the repopulation occurring after 1 day (D(prolif)) and starting after T k was estimated as 0.30 Gy/day (0.22-0.39).; CONCLUSION: The analysis confirms a high value for the alpha/b ratio. Moreover, a high intrinsic radiosensitivity together with a long kick-off time for accelerated repopulation and moderate repopulation kinetics were found. The results indicate a substantial independence of the duration of the overall treatment and an improvement in the treatment effectiveness by increasing the total dose without increasing the dose fraction.
BACKGROUND AND PURPOSE: The aim of this study was to estimate a radiobiological set of parameters from the available clinical data on glioblastoma (GB).; PATIENTS AND METHODS: A number of clinical trial outcomes from patients affected by GB and treated with surgery and adjuvant radiochemotherapy were analyzed to estimate a set of radiobiological parameters for a tumor control probability (TCP) model. The analytical/graphical method employed to fit the clinical data allowed us to estimate the intrinsic tumor radiosensitivity (alpha), repair capability (b), and repopulation doubling time (T d ) in a first phase, and subsequently the number of clonogens (N) and kick-off time for accelerated proliferation (T(k)). The results were used to formulate a hypothesis for a schedule expected to significantly improve local control. The 95 % confidence intervals (CI(95 %)) of all parameters are also discussed.; RESULTS: The pooled analysis employed to estimate the parameters summarizes the data of 559 patients, while the studies selected to verify the results summarize data of 104 patients. The best estimates and the CI(95 %) are alpha = 0.12 Gy⁻ (0.10-0.14), b = 0.015 Gy⁻ (0.013-0.020), alpha/b = 8 Gy (5.0-10.8), T(d) = 15.4 days (13.2-19.5), N = 1.10⁴(1.2.10 - 1.10⁵), and T(k) = 37 days (29-46). The dose required to offset the repopulation occurring after 1 day (D(prolif)) and starting after T k was estimated as 0.30 Gy/day (0.22-0.39).; CONCLUSION: The analysis confirms a high value for the alpha/b ratio. Moreover, a high intrinsic radiosensitivity together with a long kick-off time for accelerated repopulation and moderate repopulation kinetics were found. The results indicate a substantial independence of the duration of the overall treatment and an improvement in the treatment effectiveness by increasing the total dose without increasing the dose fraction.
Clinical radiobiology of glioblastoma multiforme: estimation of tumor control probability from various radiotherapy fractionation schemes
No results. |
Clinical radiobiology of glioblastoma multiforme: estimation of tumor control probability from various radiotherapy fractionation schemes
Other filter: ([btitle,keywords] "Accelerated Prolifer ...
Palma G, Monti S, Conson M, Pacelli R, Cella L
* Normal tissue complication probability (NTCP) models for modern radiation therapy (121 views)
Semin Oncol (ISSN: 0093-7754linking), 2019 Jun; 46(3): 210-218.
Impact Factor: 3.606
View Export to BibTeX Export to EndNote
Pedicini P, Fiorentino A, Improta G, Nappi A, Salvatore M, Storto G
* Estimate of the accelerated proliferation by protein tyrosine phosphatase (PTEN) over expression in postoperative radiotherapy of head and neck squamous cell carcinoma (291 views)
Clin Transl Oncol (ISSN: 1699-048x), 2013 Nov; 15(11): 919-924.
Impact Factor: 1.6
View Export to BibTeX Export to EndNote
Costa B, Bendinelli S, Gabelloni P, Da Pozzo E, Daniele S, Scatena F, Vanacore R, Campiglia P, Bertamino A, Gomez-Monterrey I, Sorriento D, Del Giudice C, Iaccarino G, Novellino E, Martini C
* Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor (341 views)
Plosone (ISSN: 1932-6203, 1932-6203electronic, 1932-6203linking), 2013; 8(8): e72281-e72281.
Impact Factor: 3.534
View Export to BibTeX Export to EndNote
Pedicini P, Nappi A, Strigari L, Jereczek-Fossa BA, Alterio D, Cremonesi M, Botta F, Vischioni B, Caivano R, Fiorentino A, Improta G, Storto G, Benassi M, Orecchia R, Salvatore M
* Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma (489 views)
Radiation Oncology (ISSN: 1748-717x), 2012 Sep 24; 7: 143-143.
Impact Factor: 2.107
View Export to BibTeX Export to EndNote
* Normal tissue complication probability (NTCP) models for modern radiation therapy (121 views)
Semin Oncol (ISSN: 0093-7754linking), 2019 Jun; 46(3): 210-218.
Impact Factor: 3.606
View Export to BibTeX Export to EndNote
Pedicini P, Fiorentino A, Improta G, Nappi A, Salvatore M, Storto G
* Estimate of the accelerated proliferation by protein tyrosine phosphatase (PTEN) over expression in postoperative radiotherapy of head and neck squamous cell carcinoma (291 views)
Clin Transl Oncol (ISSN: 1699-048x), 2013 Nov; 15(11): 919-924.
Impact Factor: 1.6
View Export to BibTeX Export to EndNote
Costa B, Bendinelli S, Gabelloni P, Da Pozzo E, Daniele S, Scatena F, Vanacore R, Campiglia P, Bertamino A, Gomez-Monterrey I, Sorriento D, Del Giudice C, Iaccarino G, Novellino E, Martini C
* Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor (341 views)
Plosone (ISSN: 1932-6203, 1932-6203electronic, 1932-6203linking), 2013; 8(8): e72281-e72281.
Impact Factor: 3.534
View Export to BibTeX Export to EndNote
Pedicini P, Nappi A, Strigari L, Jereczek-Fossa BA, Alterio D, Cremonesi M, Botta F, Vischioni B, Caivano R, Fiorentino A, Improta G, Storto G, Benassi M, Orecchia R, Salvatore M
* Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma (489 views)
Radiation Oncology (ISSN: 1748-717x), 2012 Sep 24; 7: 143-143.
Impact Factor: 2.107
View Export to BibTeX Export to EndNote
4 Records (3 excluding Abstracts).
Total impact factor: 10.847 (8.74 excluding Abstracts).
Total 5 year impact factor: 7.88 (5.394 excluding Abstracts).
Total impact factor: 10.847 (8.74 excluding Abstracts).
Total 5 year impact factor: 7.88 (5.394 excluding Abstracts).
387 views. Last view on Saturday 06 May 2023, 14:23:35
ibb.cnr.it
